FDA Issues Resolved, Staar Shoots For Stronger Sales Of Cataract Products
This article was originally published in The Gray Sheet
Executive Summary
Staar Surgical is committed to restoring domestic cataract product sales in 2006 after putting its regulatory woes to rest during the fourth quarter
You may also be interested in...
Staar Shakes Up U.S. Sales Force, Separating Cataract And Refractive Teams
Staar Surgical is separating its U.S. refractive and cataract product sales teams as part of a major restructuring intended to reverse the recent decline in the company's domestic revenues
Staar Shakes Up U.S. Sales Force, Separating Cataract And Refractive Teams
Staar Surgical is separating its U.S. refractive and cataract product sales teams as part of a major restructuring intended to reverse the recent decline in the company's domestic revenues
Staar Promotes Visian ICL For Myopia As Cataract Sales Decline
A successful rollout of Staar Surgical's recently FDA-approved Visian implantable contact lens (ICL) nearly offset steadily declining sales of its cataract products during the first quarter